Hairy Cell Leukemia · line 1 · Cladribine single 7-day course
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CLADRIBINE-SINGLE |
| ID | IND-HCL-1L-PENTOSTATIN |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-HCL |
| Sources | SRC-MOZ-UA-LYMPH-2013 SRC-NCCN-BCELL-2025 |
Notes
STUB — placeholder for pentostatin alternative pathway. Drug entity for pentostatin (DCF) deferred to later iteration; for now reuses REG-CLADRIBINE-SINGLE as proxy. Both purine analogs give equivalent outcomes in HCL.
Used By
Algorithms
ALGO-HCL-1L- ALGO-HCL-1L